https://doi.org/10.4081/hmr.v1i5.250

Treatment of Epstein-Barr virus-associated lymphomas: the role of Epstein-Barr virus-specific cytotoxic T cells

Vol. 1 No. 5: International Symposium on Infection-Driven Lymphomas, Rome, April 17-19, 2005
Published: May 29, 2009
Abstract Views: 149
Untitled (): 0
PDF: 272
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Helen E Heslop
support@pagepress.org
Catherine Bollard
Stephen Gottschalk
Barbara Savoldo
Malcolm K Brenne
Cliona M Rooney
Latent Epstein-Barr virus (EBV) infection is associated with a heterogeneous group of lymphoma, including Burkitt’s lymphoma, Hodgkin’s disease, NK-T lymphomas and lymphoproliferative disease (LPD).1-3 All EBV-associated malignancies are associated with the virus’ latent cycle, and three distinct types of EBV latency have been characterized.4,5 All are EBER positive, but the EBV latent protein expression varies. Latency type III, is expressed in lymphoblastoid cell lines (LCL), which can be readily produced by infecting B cells in vitro with EBV and is characterized by expression of the entire array of nine EBV latency proteins: EBNAs 1, 2, 3A, 3B, 3C, LP, BARF0 and the two viral membrane proteins LMP1 and LMP2.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Heslop, H. E., Bollard, C., Gottschalk, S., Savoldo, B., Brenne, M. K., & Rooney, C. M. (2009). Treatment of Epstein-Barr virus-associated lymphomas: the role of Epstein-Barr virus-specific cytotoxic T cells. Hematology Meeting Reports (formerly Haematologica Reports), 1(5). https://doi.org/10.4081/hmr.v1i5.250
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).